S14 Ep43: ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

In today’s episode, we had the pleasure of speaking with Stephen Liu, MD, about the potential role for zidesamtinib (NVL-520) for the treatment of patients with advanced non–small cell lung cancer (NSCLC) harboring ROS1 rearrangements. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.

In our exclusive interview, Dr Liu discussed the current standards and challenges for treating patients with ROS1-positive disease, the unique mechanism of action of zidesamtinib, and how positive findings from the phase 1/2 ARROS-1 trial (NCT05118789) may help position this agent in the ROS1-positive NSCLC treatment paradigm.